Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share. Kevin Hrusovsky, CEO of Quanterix, was with us to discuss how the company plans to revolutionize healthcare.

The fourth-leading cause of death is drug side effects, and drugs only work half the time, says Hrusovsky. He believes that if you can personalize the drugs, you have an opportunity to improve the whole pharmaceutical industry.

Quanterix is developing technology that will digitize how they see into blood, and help to see disease long before there are symptoms. Rocket science is being deployed into the blood, says Hrusovsky. He says that if you can see biomarkers and incorporate into fitbits, it can really help improve health.